Acumen Pharmaceuticals, Inc. financial data

Symbol
ABOS on Nasdaq
Location
Newton, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 655% % -62%
Debt-to-equity 38% % 115%
Return On Equity -97% % -195%
Return On Assets -70% % -151%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 60,573,425 shares 0.82%
Common Stock, Shares, Outstanding 60,573,425 shares 0.82%
Entity Public Float $97,500,000 USD -27%
Common Stock, Value, Issued $6,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 60,573,425 shares 0.82%
Weighted Average Number of Shares Outstanding, Diluted 60,573,425 shares 0.82%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $118,928,000 USD 64%
General and Administrative Expense $19,302,000 USD -5.3%
Operating Income (Loss) $138,230,000 USD -49%
Nonoperating Income (Expense) $4,879,000 USD -57%
Net Income (Loss) Attributable to Parent $133,351,000 USD -63%
Earnings Per Share, Basic -2 USD/shares -62%
Earnings Per Share, Diluted -2 USD/shares -62%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $46,832,000 USD 41%
Marketable Securities, Current $79,777,000 USD -52%
Other Assets, Current $457,000 USD 152%
Assets, Current $132,153,000 USD -36%
Property, Plant and Equipment, Net $115,000 USD 29%
Operating Lease, Right-of-Use Asset $173,000 USD -42%
Other Assets, Noncurrent $393,000 USD 131%
Assets $142,221,000 USD -47%
Accounts Payable, Current $682,000 USD -71%
Employee-related Liabilities, Current $2,778,000 USD 35%
Accrued Liabilities, Current $7,792,000 USD 58%
Liabilities, Current $21,956,000 USD 10%
Operating Lease, Liability, Noncurrent $39,000 USD -79%
Other Liabilities, Noncurrent $39,000 USD
Liabilities $49,048,000 USD -1.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax $109,000 USD -79%
Retained Earnings (Accumulated Deficit) $421,324,000 USD -46%
Stockholders' Equity Attributable to Parent $93,173,000 USD -57%
Liabilities and Equity $142,221,000 USD -47%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $34,121,000 USD -91%
Net Cash Provided by (Used in) Financing Activities $36,000 USD -101%
Net Cash Provided by (Used in) Investing Activities $28,689,000 USD
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 60,573,425 shares 0.82%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $47,064,000 USD 41%
Interest Paid, Excluding Capitalized Interest, Operating Activities $724,000 USD -4.2%
Deferred Tax Assets, Valuation Allowance $56,405,000 USD 68%
Deferred Tax Assets, Gross $56,678,000 USD 66%
Operating Lease, Liability $185,000 USD
Depreciation $15,000 USD -6.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $133,760,000 USD -66%
Operating Lease, Liability, Current $146,000 USD 13%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards $20,906,000 USD 26%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $38,000 USD -5%
Additional Paid in Capital $514,382,000 USD 1.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $273,000 USD -38%
Share-based Payment Arrangement, Expense $9,776,000 USD 9.5%
Interest Expense $1,000,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%